|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2005-5-12
|
|
pubmed:abstractText |
Alemtuzumab is a powerful lymphocyte depleting antibody currently being evaluated in solid organ transplantation. This paper describes 5-year results of a single center study of alemtuzumab as induction in renal transplantation. Thirty-three renal transplant recipients received 20 mg alemtuzumab on day 0 and 1, followed by half-dose cyclosporin monotherapy (trough concentration 75-125 ng/mL) from day 3. They were compared in a retrospective contemporaneous-controlled manner with 66 kidney transplant recipients transplanted in the same period and center who received conventional immunosuppression with cyclosporin, azathioprine and prednisolone. In the alemtuzumab group 12% of recipients died compared to 17% in the control group (p = 0.48); likewise graft loss was similar in both groups (21% vs. 26%, respectively, p = 0.58). Incidence of acute rejection was also comparable at 5 years (31.5% vs. 33.6%), although the pattern of rejection was different with 14% patients in the alemtuzumab group experiencing rejection over 1 year post-transplant compared to none in the control group. There was no significant difference between groups in terms of infection or serious adverse events. While acknowledging the limitations of a relatively small single-center study, results suggest that alemtuzumab induction allowed satisfactory long-term patient and graft survival equivalent to that seen with standard triple immunosuppression, while avoiding steroid therapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Azathioprine,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclosporine,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisolone,
http://linkedlifedata.com/resource/pubmed/chemical/alemtuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1600-6135
|
|
pubmed:author |
pubmed-author:BradleyJ AndrewJA,
pubmed-author:BradleyJohn RJR,
pubmed-author:CalneRoyR,
pubmed-author:FirthJohnJ,
pubmed-author:FriendPeter JPJ,
pubmed-author:HaleGeoffG,
pubmed-author:JamiesonNeville VNV,
pubmed-author:SmithKenneth G CKG,
pubmed-author:TaylorCraig JCJ,
pubmed-author:ThiruSathiaS,
pubmed-author:WaldmannHermanH,
pubmed-author:WatsonChristopher J ECJ
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
5
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1347-53
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15888040-Adult,
pubmed-meshheading:15888040-Aged,
pubmed-meshheading:15888040-Anti-Inflammatory Agents,
pubmed-meshheading:15888040-Antibodies, Monoclonal,
pubmed-meshheading:15888040-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:15888040-Antibodies, Neoplasm,
pubmed-meshheading:15888040-Antineoplastic Agents,
pubmed-meshheading:15888040-Azathioprine,
pubmed-meshheading:15888040-Cyclosporine,
pubmed-meshheading:15888040-Drug Therapy, Combination,
pubmed-meshheading:15888040-Female,
pubmed-meshheading:15888040-Follow-Up Studies,
pubmed-meshheading:15888040-Graft Survival,
pubmed-meshheading:15888040-Humans,
pubmed-meshheading:15888040-Immunosuppressive Agents,
pubmed-meshheading:15888040-Kidney Transplantation,
pubmed-meshheading:15888040-Male,
pubmed-meshheading:15888040-Middle Aged,
pubmed-meshheading:15888040-Postoperative Complications,
pubmed-meshheading:15888040-Prednisolone,
pubmed-meshheading:15888040-Remission Induction,
pubmed-meshheading:15888040-Retrospective Studies,
pubmed-meshheading:15888040-Safety,
pubmed-meshheading:15888040-Time Factors,
pubmed-meshheading:15888040-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
|
|
pubmed:affiliation |
University of Cambridge, Department of Surgery, Addenbrooke's Hospital, UK. cjew2@cam.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
